BioMed Research International / 2019 / Article / Fig 6

Research Article

Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation

Figure 6

Effects of etifoxine on SREBP-1 and apoJ protein levels. (a and c) Huh7.5-SEAP cells (7 × 105) were infected with 0.01 MOI of HCV and treated with etifoxine (0.01-1 μM) in a 6-well plate for 6 days after treatment. Cell lysates were collected and the SREBP-1, apoJ, and β-actin levels were detected by Western blot. (b) Cells were infected with HCV and treated with 1 μM of etifoxine for 6 days in a 24-well plate. Cells (1.5 x 104) were fixed with paraformaldehyde on day 6, stained with core and SREBP-1 antibodies, counterstained with DAPI, and then observed under confocal laser scanning microscope. Scale bar: 50 μM. The arbitrary units (AU) of immunofluorescence intensity normalized with the number of cells were assessed using Image J. Six fields per each group were randomly chosen and each field, containing approximately 15-20 cells, was amplified 40 fold in order to observe core protein expression and SREBP-1 translocation to nucleus. Data are expressed as mean ±SD obtained from three individual experiments. < 0.05 and < 0.001 vs. the medium control group; #p < 0.05 and ##p < 0.01 vs. the HCV-infected Huh 7.5-SEAP group.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.